Cooperation Centre for Scientific Research Relative to Tobacco
Centre de Coopération pour les Recherches Scientifiques Relatives au Tabac

FDA regulates tobacco products based on a public health standard that considers the risks and benefits of the tobacco product on the population as a whole. A part of this consideration includes the evaluation of a tobacco product’s abuse liability,...

The U.S. Food and Drug Administration (FDA) recommends that tobacco product manufacturers provide information regarding the abuse liability of tobacco and nicotine-containing products to support pre-market tobacco, modified risk tobacco product and...

The objectives of this clinical study were to demonstrate a reduction in exposure to selected harmful and potentially harmful constituents (HPHCs) in Japanese healthy adult smokers who switched to four in-market heated tobacco products. Eighty-nine...

The Controlled Substances Act (CSA) describes eight factors that need to be examined to assess the abuse potential (or liability) of drugs in clinical development that are active within the central nervous system (CNS). These factors encompass a wide...

Abstract not available.   Link to Symposium Recording  ...

Although globally prohibited for over a century, humans have been using cannabis and its multitude of extracts and preparations for many millennia. With countries and states around the world decriminalizing or legalizing cannabis for medical and/or...

Reference only. Abstract submission was on a voluntary basis....

Reference only. Abstract submission was on a voluntary basis....

Reference only. Abstract submission was on a voluntary basis....

Reference only. Abstract submission was on a voluntary basis....